Therapeutically, strategies aiming to restore CASP1 activity, deplete or inhibit FOXP3+ Tregs, or target PDIA3-related antigen presentation defects could enhance immune surveillance and improve responsiveness to immunotherapy in multiple cancer types. The gene discussed is FOXP3; the disease is cancer.